Know Cancer

or
forgot password

Clinical Study to Evaluate a Protocol of Oxaliplatin -UFT- Radiotherapy for the Neoadjuvant Treatment Rectal Cancer


Phase 1/Phase 2
18 Years
75 Years
Not Enrolling
Both
Rectal Neoplasms

Thank you

Trial Information

Clinical Study to Evaluate a Protocol of Oxaliplatin -UFT- Radiotherapy for the Neoadjuvant Treatment Rectal Cancer


The following information on clinical trials is provided for information purposes only to
allow patients and physicians to have an initial discussion about the trial. This
information is not intended to be complete information about the trial, to contain all
considerations that may be relevant to potential participation in the trial, or to replace
the advice of a personal physician or health professional.

Main criteria are listed hereafter:

Inclusion Criteria:



- Patients with measurable, histologically proven rectal cancer.

- No history of previous malignancy but adequately treated skin / cervical cancer.

- Adequate haematological, renal and liver function.

Exclusion Criteria:

- No cardiopulmonary insufficiency or coronary disease. No sensory neuropathy prior to
study.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Tumour response

Principal Investigator

José Mª Taboada, Dr.

Investigator Role:

Study Director

Investigator Affiliation:

Sanofi

Authority:

Spain: Spanish Agency of Medicines

Study ID:

L_8128

NCT ID:

NCT00403624

Start Date:

July 2001

Completion Date:

November 2005

Related Keywords:

  • Rectal Neoplasms
  • Neoplasms
  • Rectal Neoplasms

Name

Location